Carlos Ferreira

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.